Mobile App for Improving Adherence of Rivoxaban (RIVOX-AF)

The ReInforcement of Adherence Via Self-monitoring App Orchestrating Biosignals and Medication of RivoXaban in Patients With Atrial Fibrillation and Co-morbidities: Randomised Control Study(RIVOX-AF Study)

RIVOX-AF study is a prospective, multicenter, randomized controlled study in which patients with AF are allocated to medication-app group or conventional treatment group. The App based feed-back algorithm will provide the patients with check taking drug or reminding of taking drug.

Inclusion Criteria:

• Patients with AF aged 19 years or older with one or more comorbidities including heart failure, myocardial infarction, stable angina, hypertension or diabetes mellitus (Patients can be enrolled 3 months after myocardial infarction or percutaneous coronary intervention).
• patients who already took or plan to take rivoxban
• patients who able to use smart phone

Exclusion Criteria:

• creatinine clearance <15ml/min
• moderate or severe mitral stenosis
• mitral valve operation history
• current alcohol abuse or alcohol abus history
• Not eligible for study due to legal or psychiatric problem
• enrolled other clinical study within 4 weeks
• declined to enroll the study